Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th

About this update from Telo Genomics Corp.

[{"type":"text","content":"Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9thCompany invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com\n\n\n\n TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), based in Toronto, a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics platform, today announced that Guido Baechler, Executive Chairman, will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on December 9\n \n th\n \n .\n \n\n\n DATE\n \n : December 9\n \n th\n \n\n\n TIME: 2:30 PM ET\n \n\n\n LINK:\n \n\n\n REGISTER HERE\n \n\n\n Available for 1x1 meetings: December 16. Schedule 1x1 Meetings\n \n here\n \n\n\n This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.\n \n\n It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.\n \n\n Learn more about the event at\n \n\n www.virtualinvestorconferences.com\n \n\n .\n \n\n\n Recent Company Highlights\n \n\n\n\n Initiated a multiple myeloma MRD clinical trial in collaboration with Cleveland Clinic Cancer Institute using Telo’s 3D telomere analysis.\n \n\n Presented poster at IMS 2025 highlighting Telo’s new MRD methodology using 3D telomere profiling of liquid biopsy as a predictive marker of disease progression.\n \n\n Relocated from the MaRS hub into a larger, state-of-the-art clinical lab in the GTA\n \n\n Presented at the Myeloma Canada MRD Implementation Summit, showcasing Telo’s individual-cell risk assessment (ICRA) MRD technology with initial clinical data\n \n\n Presented interim MM-MRD data from Cleveland clinic study data at the American Society of Hematology Annual Meeting\n \n\n\n\n\n\n About Telo Genomics\n \n\n Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in on...

More updates from Telo Genomics Corp.